SMS Pharmaceuticals Ltd
SMS Pharmaceuticals Q3 FY25: Revenue ₹173.35 Cr, PAT ₹18.24 Cr
Q3 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on SMS Pharmaceuticals Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). EBITDA for Q3FY25: ₹33.21 crore, up 15% YoY (Page 18 & 5) - EBITDA Margin for Q3FY25: 19%, up 120 bps YoY (Page 18 & 5) - Profit After Tax (PAT) for Q3FY25: ₹18.24 crore, up 59% YoY (Page 18 & 5) - PAT Margin for Q3FY25: 11%, up 341 bps YoY (Page 18) - Operating margin/outlook: The presentation notes margin expansion aided by backward integration and favorable product mix (Page 18).
From SMS Pharmaceuticals Ltd's Q3 FY25 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5).
- Volume growth cited as a driver for revenue increase across the product portfolio (Page 18).
- 9MFY25 revenue at ₹534.55 crore, up 15% YoY from ₹463.47 crore in 9MFY24 (Page 18).
- EBITDA grew 15% YoY with margin expansion; PAT increased 59% YoY (Page 4, 5).
- No explicit quarterly or yearly volume figures stated, only qualitative mention of strong volume growth (Page 18).
- Outlook states "Robust growth is expected in revenue and profitability" driven by portfolio approach and cost optimization (Page 17).
- Capacity expansion and backward integration projects underway aiming to boost production scale (Page 16).
2 more points management made on revenue & sales performance
Profitability & Margins
See what SMS Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing capex of ₹150 crore focused on backward integration and capacity expansion (Page 16).
- Aim to achieve a production target of 1,000 MT per month for ibuprofen to achieve global scale (Page 16).
- 2nd phase of backward integration project is complete; trial runs ongoing with commercial production set for March 2025 (Page 4).
- Capacity expansion project remains on track for completion by FY26 (Page 4).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what SMS Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
SMS Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What SMS Pharmaceuticals Ltd's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem Ltd (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Remedies Ltd (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare Ltd (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Frequently Asked Questions
What were SMS Pharmaceuticals Ltd Q3 FY25 results?
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). EBITDA for Q3FY25: ₹33.21 crore, up 15% YoY (Page 18 & 5) - EBITDA Margin for Q3FY25: 19%, up 120 bps YoY (Page 18 & 5) - Profit After Tax (PAT) for Q3FY25: ₹18.24 crore, up 59% YoY (Page 18 & 5) - PAT Margin for Q3FY25: 11%, up 341 bps YoY (Page 18) - Operating margin/outlook: The presentation notes margin expansion aided by backward integration and favorable product mix (Page 18).
What is SMS Pharmaceuticals Ltd share price analysis?
SMS Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 40.5 with a market cap of ₹4,148 Cr. Investors should review the full earnings analysis for detailed insights.
Is SMS Pharmaceuticals Ltd planning capital expenditure?
Ongoing capex of ₹150 crore focused on backward integration and capacity expansion (Page 16).
Keep SMS Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.